Once again, the U.S. Supreme Court finds itself at the center of a national case involving access to abortion, this time around the drug mifepristone, which along with misoprostol forms part of the regimen for a so-called medication abortion. Its ruling is expected in June, and that ruling should be clear, if only to help clean up the mess it created with its overturning of Roe v. Wade a year and a half ago.
For a body that had insisted its Dobbs ruling would finally and definitively send the question of abortion to the states, it has often found itself dragged back to the debate. This should come as no surprise; it was obvious even before Dobbs was leaked that the radical groups and officials hell-bent on taking away this medical choice from women would not be satisfied with doing so only within the confines of certain states.
Since Roe was first issued 50 years ago, the anti-choice movement have been very clear that they will not rest until not only is that precedent dead and buried — mission accomplished now on that — but until it is impossible for a woman or girl to avail herself of abortion care anywhere in the country, for any reason.
That is precisely why state officials have, for example, endeavored to prevent women from leaving states with abortion bans for others where the care is legal; it’s clearly not about state sovereignty but control over access wholesale.
In this case, the Alliance for Hippocratic Medicine — a preposterously named organization that in contrast to its moniker is in fact seeking to do plenty of harm — and other pseudo-medical organizations are suing the Food and Drug Administration over its 2000 approval and subsequent use authorizations of mifepristone.
